Navigation Links
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team

NEW YORK, July 8 /PRNewswire/ -- Royalty Pharma is pleased to announce that James Reddoch, Ph.D., has joined the company as Executive Vice President, Head of Research. Dr. Reddoch has 17 years of experience in the biotechnology sector. He has spent the last 12 years as an equity analyst, most recently as Managing Director, Biotechnology and Group Head, Healthcare, at FBR Capital Markets. He previously worked at Banc of America Securities, and CIBC World Markets Corp. (now Oppenheimer & Co.). Dr. Reddoch holds a B.A. from Furman University and a Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine.

(Logo: )

"The addition of Jim to our management team adds a critical element to our analytical capabilities. He combines a deep scientific knowledge with fundamental research and financial skills," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "As an analyst, Dr. Reddoch has proven to have a unique perspective that has differentiated him from his peers."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with approximately $5 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Abbott's Humira(R), J&J/Centocor's Remicade(R), Pfizer's Lyrica(R), Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

The company has an eleven year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica(R) royalty from Northwestern University, its $650 million purchase of the Remicade(R) royalty from New York University, its $700 million purchase of the Humira(R) royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen(R) and Neulasta(R) for over $400 million.

For more information, go to


Pablo Legorreta, Chief Executive Officer

Alexander B. Kwit, Executive Vice President and General Counsel

Susannah Gray, Executive Vice President and Chief Financial Officer


SOURCE Royalty Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech to Establish Separate Operating and Royalty Businesses
2. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
3. Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Childrens Hospital Foundation for $182 Million
4. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
5. Antibody Engineering Company F-Star Buys Back Royalty Obligations
6. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
7. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
8. Drug Royalty Corporation Changes Its Name to DRI Capital
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
11. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):